Division of General Internal Medicine, Mount Sinai School of Medicine, 1 Gustave Levy Place, New York City, NY 10029, USA.
Ethn Health. 2011 Aug-Oct;16(4-5):431-45. doi: 10.1080/13557858.2011.558619.
The lack of matched sibling donors poses a significant barrier to utilizing hematopoietic cell transplantation (HCT), the only proven cure for children with sickle cell disease (SCD). Little is known about current patient and parent perspectives towards HCT for SCD. This study examines the perceived barriers of transplant, and the use of in vitro fertilization (IVF) and preimplantation genetic diagnosis (PGD), when there is no pre-existing sibling donor.
Semi-structured interviews were conducted with adult patients with SCD and parents of children with SCD in an urban medical center in the US. Transcribed data was analyzed using qualitative methods.
Of 23 participants, 17 reported having heard of HCT for SCD. Fewer knew of IVF or PGD as a means for conceiving an unaffected child (n =7) or to select a potential umbilical cord blood donor (n =1). The financial cost of IVF and PGD was perceived as a significant initial barrier to accessing these technologies, with the clinical risks of HCT and the ethical appropriateness of using PGD also identified as barriers. The value of informing families of these options was a recurring theme, even among respondents who personally disagreed with their application.
The low utilization of curative strategies for SCD appears to be partly attributable to a lack of information about the technologies available to facilitate transplantation. Ethical reservations, while present, were not static and did not preclude patients' and parents' desire to be informed. We discuss the implications of these perceived barriers to the dissemination of advanced medical technologies for SCD.
缺乏匹配的同胞供者是利用造血细胞移植(HCT)的一个重大障碍,HCT 是治疗镰状细胞病(SCD)儿童的唯一有效方法。目前,人们对患者和家长对 SCD 进行 HCT 的看法知之甚少。本研究调查了在没有预先存在的同胞供者时,对移植的感知障碍,以及体外受精(IVF)和植入前遗传学诊断(PGD)的应用。
在美国的一家城市医疗中心,对成年 SCD 患者和 SCD 儿童的家长进行了半结构式访谈。使用定性方法对转录数据进行了分析。
在 23 名参与者中,有 17 名报告听说过 SCD 的 HCT。了解 IVF 或 PGD 作为一种生育非受影响儿童(n=7)或选择潜在脐带血供者(n=1)的方法的人较少。IVF 和 PGD 的财务成本被认为是获得这些技术的一个重大初始障碍,HCT 的临床风险和使用 PGD 的伦理适当性也被认为是障碍。向家庭提供这些选择的价值是一个反复出现的主题,即使在对其应用个人持不同意见的受访者中也是如此。
SCD 治疗策略的低利用率部分归因于缺乏有关促进移植的可用技术的信息。尽管存在伦理保留意见,但它们并不是静态的,并不排除患者和家长了解的愿望。我们讨论了这些感知障碍对 SCD 先进医疗技术传播的影响。